EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis

Luke D Tyson iD, Stephen Atkinson, Benjamin H Mullish iD, Alexandros Pechlivanis, Michael Allison, Andrew Austin, Katie Chappell, Stuart J Forbes, Ewan H Forrest, Alastair M Kilpatrick, Tong Liu, Laura Martinez-Gili and 11 more

Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (12) · 1658-1672

DOI: 10.1111/apt.70616 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-03-23. Written by Luke D Tyson and 22 co-authors. Institution: Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. Major MEDLINE topics: Bile Acids and Salts, Hepatitis, Alcoholic, Liver Cirrhosis, Alcoholic. Cited 1 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research, NIHR Imperial Biomedical Research Centre, Health Technology Assessment Programme.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Alcohol‐related hepatitis (AH) is characterised by acute cholestasis and liver dysfunction in patients consuming alcohol.

Aims

To define the bile acid (BA) profile in AH compared to decompensated alcohol‐related cirrhosis (DC) and healthy controls (HC).

Methods

Serum and faecal BAs were measured by UHPLC–MS; FGF19 by ELISA; RNA‐sequencing data obtained from liver biopsies; serum cytokines and growth factors quantified by multiplex immunoassay. Hepatocyte growth factor (HGF) was applied to primary human hepatocytes (PHH) and BA transporter expression was assessed by RT‐qPCR.

Results

In two cohorts (Cohort 1: 164 AH, 63 DC, 36 HC; Cohort 2: 94 AH, 175 DC, 72 HC), total serum BAs were highest in AH (median concentration 186.0 μM vs. 64.5 DC vs. 5.0 HC), driven by elevated conjugated primary BAs (182.0 μM vs. 54.0 vs. 2.2). Unconjugated primary BAs were highest in DC. Serum BAs distinguished AH from DC (Cohort 1 AUROC 0.964; Cohort 2 0.922; p < 0.001). Faecal BAs were reduced in AH (0.47 mg/g vs. 1.11 DC vs. 2.64 HC); serum FGF19 elevated (5835 pg/mL AH vs. 865 jaundiced DC [bilirubin > 80 μmol/L]). Serum conjugated BAs correlated negatively with NTCP expression ( n = 25, Spearman's rho −0.432, p = 0.031). CYP7A1 was below the limit of detection. HGF was elevated in AH (7899 pg/mL vs. 2607 DC, p < 0.001). HGF treatment reduced PHH BSEP expression.

Conclusion

Serum conjugated primary BAs accumulate in AH. Elevated HGF may detrimentally affect the hepatoprotective adaptive reduction in NTCP/increase in BSEP seen in cholestasis, contributing to the AH BA profile.

Subjects

MeSH terms (MEDLINE)

Bile Acids and SaltsHepatitis, AlcoholicLiver Cirrhosis, AlcoholicHumansMaleFemaleMiddle AgedHepatocyte Growth FactorHepatocytesFibroblast Growth FactorsAdultFecesCase-Control StudiesAged

Author keywords

alcohol‐associated hepatitisalcohol‐related hepatitisbile acidsfibroblast growth factor 19hepatocyte growth factor

Substances

Bile Acids and SaltsHepatocyte Growth FactorFibroblast Growth FactorsFGF19 protein, human

Authors and institutions

  • Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Imperial College Healthcare NHS Trust, St Mary's Hospital, The Liver Unit, London, UK.
  • GSK, Brentford, UK.
  • Cambridge NIHR Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK.
  • Department of Hepatology, Royal Derby Hospital, Derby, UK.
  • Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.

ORCID profiles: Luke D Tyson, Benjamin H Mullish, Mark J W McPhail, Nikhil Vergis

Funding

  • National Institute for Health and Care Research
  • NIHR Imperial Biomedical Research Centre
  • Health Technology Assessment Programme
  • Imperial College Healthcare NHS Trust
  • Imperial College London
  • Medical Research Council

Cite

APA

Tyson, L. D., Atkinson, S., Mullish, B. H., Pechlivanis, A., Allison, M., Austin, A., Chappell, K., Forbes, S. J., Forrest, E. H., Kilpatrick, A. M., Liu, T., Martinez-Gili, L., Masson, S., McPhail, M. J. W., Nunes, J., Richardson, P., Rodrigo-Torres, D., Ryder, S. D., Wright, M., …, & Thursz, M. R. (2026). Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis. Alimentary Pharmacology & Therapeutics, 63(12), 1658-1672. https://doi.org/10.1111/apt.70616

Vancouver

Tyson LD, Atkinson S, Mullish BH, Pechlivanis A, Allison M, Austin A, et al. Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis. Alimentary Pharmacology & Therapeutics. 2026;63(12):1658-1672. doi:10.1111/apt.70616

BibTeX
@article{Tyson2026,
  author = {Tyson, Luke D and Atkinson, Stephen and Mullish, Benjamin H and Pechlivanis, Alexandros and Allison, Michael and Austin, Andrew and Chappell, Katie and Forbes, Stuart J and Forrest, Ewan H and Kilpatrick, Alastair M and Liu, Tong and Martinez-Gili, Laura and Masson, Steven and McPhail, Mark J W and Nunes, Joao and Richardson, Paul and Rodrigo-Torres, Daniel and Ryder, Stephen D and Wright, Mark and Patel, Vishal C and Vergis, Nikhil and Holmes, Elaine and Thursz, Mark R},
  title = {Disordered Bile Acid Metabolism in Alcohol‐Related Hepatitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {12},
  pages = {1658--1672},
  doi = {10.1111/apt.70616}
}
Start for free →